Figure 1.

Design and characterization of the CD19 CAR. (A) Schematic of the CD19-specific CAR, which was held on the cell surface via a CD8α hinge stalk and signaled through CD28 and CD3ζ endodomains. (B) Characterization of the infusion product. Patient derived CAR⁺ T-cells were generated by co-culture of genetically modified T-cells with K562 AaPCs. Cells were phenotyped and enumerated every 7 days. The total cells generated and percent CAR and CD3 expression of the cell products at time of cryopreservation is shown. (C) Expansion kinetics of all the manufactured patient derived CAR⁺ T-cells over time. Each symbol represents an individual patient.